Zevra Therapeutics, Inc.

General ticker "ZVRA" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $459.3M (TTM average)

Zevra Therapeutics, Inc. follows the US Stock Market performance with the rate: 37.1%.

Estimated limits based on current volatility of 2.3%: low 8.45$, high 8.85$

Factors to consider:

  • Total employees count: 69 as of 2023
  • Price in estimated range
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [5.90$, 12.28$]
  • 2025-12-31 to 2026-12-31 estimated range: [5.14$, 10.93$]

Financial Metrics affecting the ZVRA estimates:

  • Negative: with PPE of -3.8 at the end of fiscal year the price was high
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -17.84 <= 0.33
  • Positive: 18.93 < Shareholder equity ratio, % of 22.27 <= 41.86
  • Negative: negative Net income
  • Positive: -14.38 < Investing cash flow per share per price, % of -5.67
  • Positive: Interest expense per share per price, % of 1.88 <= 3.41
  • Negative: -0.15 < Industry inventory ratio change (median), % of 0
  • Positive: Inventory ratio change, % of -39.02 <= -0.75

Similar symbols

Short-term ZVRA quotes

Long-term ZVRA plot with estimates

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $10.16MM $27.46MM $23.61MM
Operating Expenses $52.73MM $77.06MM $110.61MM
Operating Income $-42.56MM $-49.60MM $-87.00MM
Non-Operating Income $15.76MM $3.56MM $-3.14MM
Interest Expense $0.34MM $1.50MM $7.35MM
R&D Expense $19.80MM $39.81MM $42.09MM
Income(Loss) $-26.80MM $-46.05MM $-90.14MM
Taxes $-0.03MM $0.00MM $15.37MM
Profit(Loss)* $-12.00MM $-46.05MM $-105.51MM
Stockholders Equity $75.12MM $61.86MM $39.67MM
Inventory $0.00MM $24.08MM $1.97MM
Assets $115.34MM $172.33MM $178.13MM
Operating Cash Flow $-18.72MM $-33.53MM $-69.67MM
Capital expenditure $0.09MM $0.30MM $0.00MM
Investing Cash Flow $-36.72MM $-17.39MM $-22.16MM
Financing Cash Flow $8.35MM $28.46MM $82.11MM
Earnings Per Share** $-0.35 $-1.30 $-2.28

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.